Our mission
Why eye movements
5 min
Exam of the eye movements tells more than a kilometer walk
5 years
Eye movements help predict disease evolution up to 5 years
110 000
scientific papers link eye-tracking with disorders
neuroClues®
An easy-to-use eye-tracking environment
to help practitioners instantaneously quantify their clinical exam
Based on years of research, it is designed to bring non-invasive, quick, and robust biomarkers.
neuroClues® has the ambition to provide:
- A better diagnosis thanks to its sensitivity for early detection and specificity for ruling out differential diagnosis
- A better follow-up of the patients with its objective measurements of the evolution of the disease and the efficacy of the treatment
- An intuitive research tool with high spatial and temporal resolution
neuroClues® is a registered brand of P3Lab, currently under research and development phase. It will be available for sale when regulatory clearance is received.
Testimonials
Our scientific advisory board testifies
About eye-tracking
Over the last 60 years, over 110 000 scientific articles have been written linking eye movement to neurological diseases
Eye-tracking enables measurements and analysis, allowing neurologists to increase their diagnosis certainty in few minutes and have a better follow-up of the patients. This innovative technology can be used for the diagnosis of Parkinson’s disease and other neurological diseases.
Latest news
SfN poster: Evidence of an exogenous input to Superior Colliculus as a source of saccadic inhibition.
In this poster, presented at the Society for Neuroscience 2023 annual meeting (SfN23) in Washington DC, we provide preliminary evidence for the potential of a specific
Your guide to navigating SfN 2023 in Washington DC
Your guide to navigating the SfN Welcome to Washington DC ! As the Society for Neuroscience’s annual meeting approaches, we are excited to present
The eyes: mirrors of the soul, but above all of how our brain works. A guest opinion in ADN.
An article written by our co-founders Antoine Pouppez and Pierre Pouget, and published on ADN: NeuroClues, a start-up developing a medical device based on eye-tracking,
Clinical highlights: Spinocerebellar Ataxia
The newsletter of this month will emphasize the latest research about Spinocerebellar Ataxia
